Xie, Yuchen
Sahin, Merve http://orcid.org/0000-0003-3858-8332
Sinha, Sonali
Wang, Yufeng
Nargund, Amrita M.
Lyu, Yang
Han, Song
Dong, Yiyu http://orcid.org/0000-0002-5391-4936
Hsieh, James J. http://orcid.org/0000-0003-3595-0551
Leslie, Christina S. http://orcid.org/0000-0002-4571-5910
Cheng, Emily H. http://orcid.org/0000-0002-3595-2648
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F99 CA234949, R01 CA223231, P30 CA008748)
Article History
Received: 19 February 2020
Accepted: 24 November 2021
First Online: 3 February 2022
Competing interests
: J.J.H. has consulted for Eisai and BostonGene and has received clinical trial funding from Bristol Myers Squibb, Merck, AstraZeneca, Exelixis, Calithera and SillaJen. J.J.H. has received research funding from Merck, BostonGene and TScan. All other authors have no competing interests to declare.